Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hargrove

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
American Journal of Physiology. Endocrinology and Metabolism|October 7, 2010
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodentsKrystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 21, 2020
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel SyndromeDiane M Hargrove, Sudarkodi Alagarsamy, Glenn Croston, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodentsK Tatarkiewicz, D M Hargrove, C M Jodka, et al.
Regulatory Peptides|February 13, 2007
Biological activity of AC3174, a peptide analog of exendin-4Diane M Hargrove, Eric S Kendall, James M Reynolds, et al.
Headache|June 14, 2023
Randomized controlled pilot trial of prazosin for prophylaxis of posttraumatic headaches in active-duty service members and veteransCindy L Mayer, Paul J Savage, Conner K Engle, et al.
Journal of Medicinal Chemistry|February 21, 2003
In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonistRichard L Elliott, Robert M Oliver, Marlys Hammond, et al.
The Journal of Biological Chemistry|July 5, 2003
Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animalsH James Harwood, Stephen F Petras, Lorraine D Shelly, et al.
Journal of Medicinal Chemistry|March 18, 2016
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic ClearanceKazimierz Wiśniewski, Javier Sueiras-Diaz, Guangcheng Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimeticsRobert L Dow, Steven R Schneider, Ernest S Paight, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
American Journal of Physiology. Endocrinology and Metabolism|October 7, 2010
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodentsKrystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 21, 2020
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel SyndromeDiane M Hargrove, Sudarkodi Alagarsamy, Glenn Croston, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodentsK Tatarkiewicz, D M Hargrove, C M Jodka, et al.
Regulatory Peptides|February 13, 2007
Biological activity of AC3174, a peptide analog of exendin-4Diane M Hargrove, Eric S Kendall, James M Reynolds, et al.
Headache|June 14, 2023
Randomized controlled pilot trial of prazosin for prophylaxis of posttraumatic headaches in active-duty service members and veteransCindy L Mayer, Paul J Savage, Conner K Engle, et al.
Journal of Medicinal Chemistry|February 21, 2003
In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonistRichard L Elliott, Robert M Oliver, Marlys Hammond, et al.
The Journal of Biological Chemistry|July 5, 2003
Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animalsH James Harwood, Stephen F Petras, Lorraine D Shelly, et al.
Journal of Medicinal Chemistry|March 18, 2016
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic ClearanceKazimierz Wiśniewski, Javier Sueiras-Diaz, Guangcheng Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimeticsRobert L Dow, Steven R Schneider, Ernest S Paight, et al.
Pageof 8